A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F12%3A43905285" target="_blank" >RIV/00216208:11120/12:43905285 - isvavai.cz</a>
Alternative codes found
RIV/00064211:_____/12:#0000125
Result on the web
<a href="http://dx.doi.org/10.1007/s00280-011-1771-0" target="_blank" >http://dx.doi.org/10.1007/s00280-011-1771-0</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00280-011-1771-0" target="_blank" >10.1007/s00280-011-1771-0</a>
Alternative languages
Result language
angličtina
Original language name
A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
Original language description
This is a phase I study of the retinoid X receptor agonist bexarotene (Targretin) in combination with the chemotherapeutic drugs cisplatin and vinorelbine and lipid-lowering therapy. This study looked for pharmacokinetic (PK) interactions between the agents in parallel with a phase III study of the combination. Methods: Patients (n = 26) with advanced-stage non-small-cell lung cancer received intravenous cisplatin 100 mg/m2 on day 1 and at 4-week intervals plus intravenous vinorelbine 25 mg/m2 weekly. Continuous oral bexarotene therapy (400 mg/m2/day) was initiated at day 4. Lipid-lowering therapy was initiated in all patients due to hypertriglyceridemia associated with bexarotene use. PK profiles of the chemotherapeutic agents were obtained on day 1 (without bexarotene) and during cycles 2-4 (with bexarotene). Vinorelbine (n = 18) and free cisplatin (n = 17) PK parameters in evaluable patients were determined using non-compartmental methods. Results: Mean vinorelbine and free cisplati
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FC - Pneumology
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cancer Chemotherapy and Pharmacology
ISSN
0344-5704
e-ISSN
—
Volume of the periodical
69
Issue of the periodical within the volume
3
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
815-824
UT code for WoS article
000302325600025
EID of the result in the Scopus database
—